JP2006022055A - Eye washing set - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an eye washing set that prevents contamination of an eye washing cup and keeps a clean state. <P>SOLUTION: The eye washing set is obtained by combining an eye washing liquid that contains at least one or more kinds selected from the group consisting of chondroitin sulfuric acid or its salt, glycyrrhizinic acid or its salt, acetic acid tocopherol, aspartic acid or its salt, epsilon-aminocaproic acid or its salt and aminoethylsulfonic acid or its salt and has ≥2mPa×s and ≤15 mPa×s viscosity at 20°C with an eye washing cup. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to an eye wash set in which microbial adhesion to an eye wash cup is suppressed.

  Eye washing is widely performed to clean the conjunctival sac and prevent eye diseases. Washing eyes is effective in eliminating eye grease, pollen and dust, and bacteria in the conjunctival sac to eliminate eye discomfort and preventing eye infections.

  By the way, according to a general eye wash method, first, about 5 to 10 ml of eye wash is poured into the eye wash cup, and then the eye wash cup opening edge is pressed against the eye to open and close the eyelid in the eye wash or within the eye wash cup. Wash the eyes with water flow. These eyewash solutions and eyewash cups are usually sold as a set of eyewash sets. The user divides the eyewash into the eyewash cup and uses it. However, since one eyewash cup is used repeatedly, it is difficult to avoid microbial contamination of the eyewash cup due to various bacteria contained in the liquid after eye washing. In addition, there is no custom of washing the eyewash cup thoroughly with detergent, etc., and storing the eyewash cup after each use, so that the microorganisms once adhered can grow without being removed and digest plastic. There was a risk of intrusion.

  The eye wash contains surfactants, etc., and a prescription design with a high eye wash effect has been devised, while the eye wash cup material selection emphasizes the feeling of use when pressing around the eyes, so microorganisms Often used is a soft plastic that easily adheres. When a contaminated eyewash cup is used, it may cause eye infections or cause eye irritation, especially in damaged eye tissues.

  In order to solve these problems, a unit-dose eyewash cup that can always keep the eyewash cup clean is known (Patent Document 1). The unit-dose eyewash cup is disposable, so it is excellent in that it can always be used in a clean state, but lacks versatility because of its high cost. In addition, a method of directly spraying eyewash on the eyes is known (Patent Document 2). Although this method does not require an eyewash cup, spraying the compressed gas directly on the eye still has a problem from the viewpoint of safety.

JP 2003-190249 A Japanese Patent Laid-Open No. 10-230007

  An object of the present invention is to solve the above-described problems and to provide an eyewash set that can keep the eyewash cup clean even when the eyewash cup is used repeatedly and that is highly safe for the eyes.

  As a result of intensive studies for solving the problems, the present inventors have found that chondroitin sulfate or a salt thereof, glycyrrhizic acid or a salt thereof, tocopherol acetate, aspartic acid or a salt thereof, epsilon aminocaproic acid or a salt thereof, and aminoethylsulfonic acid or a salt thereof. By using an eye wash containing at least one selected from the group consisting of salts and having a viscosity at 20 ° C. of 2 mPa · s to 15 mPa · s, microorganism adhesion to the eye wash cup is suppressed, and the eye wash cup Has been found to be clean, and the present invention has been completed.

The present inventor has been developed based on such knowledge.
That is, the present invention is an eye wash set listed in the following (1) to (5).
(1) at least one selected from the group consisting of chondroitin sulfate or a salt thereof, glycyrrhizic acid or a salt thereof, tocopherol acetate, aspartic acid or a salt thereof, epsilon aminocaproic acid or a salt thereof, and aminoethylsulfonic acid or a salt thereof An eye wash set comprising an eye wash cup containing an eye wash having a viscosity at 20 ° C. of 2 mPa · s to 15 mPa · s.
(2) The eyewash set according to (1), wherein the eyewash has a viscosity at 20 ° C. of from 3 mPa · s to 10 mPa · s,
(3) The eye wash set according to (1) or (2), wherein the eye wash contains at least one selected from the group consisting of hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone and polyvinyl alcohol,
(4) The eye wash further contains a nonionic surfactant selected from polyoxyethylene-polyoxypropylene block copolymers, polyoxyethylene sorbitan fatty acid esters or polyoxyethylene hydrogenated castor oils (1) to (1) to The eye wash set according to (3),
(5) The eye wash set according to any one of (1) to (4), wherein the eye wash further contains edetic acid or a salt thereof,
(6) The eye wash set according to any one of (1) to (5), wherein the eye wash further contains at least one selected from menthol, camphor, geraniol, or borneol.
In the present specification, unless otherwise specified,% means w / v%.

  The eye wash set of the present invention can suppress the adhesion of microorganisms to the eye wash cup. Therefore, it prevents contamination of the eyewash cup and keeps it clean even after repeated use, so it is safe without causing eye infections or causing eye irritation even in damaged eye tissues. Is expensive.

  The eye wash set of the present invention is an eye wash set comprising a combination of an eye wash and an eye wash cup contained in a container. In addition to these, an outer cover of the eyewash container and an auxiliary tool for an eyewash cup may be combined to make a set.

  Such an eyewash cup has an opening that can be pressed around the eye, and various synthetic resins and natural resins can be used as the material thereof. Examples include resins used for medical devices, such as polyvinyl chloride, acrylonitrile butadiene styrene resin, polyethylene, polycarbonate, polypropylene, polystyrene, synthetic rubber, natural rubber, methacrylic resin, silicone, silicone rubber, polyurethane, polymer gel, Polyethylene trifluoride, thermoplastic elastomer, polyvinyl alcohol, polytetrafluoroethylene, epoxy resin, polyethylene terephthalate, polyamide, polyacetal, polyvinylidene fluoride, urea resin, polyvinyl acetate, polyethylene terephthalate, polyethylene naphthalate, polycarbonate, phenol Resins, alkyd resins, melamine resins, cyanoacrylates, acrylic resins and the like can be mentioned. Among these, polyvinyl chloride, low-substituted polyethylene, polystyrene, synthetic rubber, methacrylic resin, silicone resin, polyurethane, polytrifluorinated ethylene, thermoplastic elastomer, and polytetrafluoroethylene are preferable, and low-substituted polyethylene and thermoplastic are preferred. Elastomeric silicone resin and synthetic rubber are particularly preferred.

  The eye wash set of the present invention is selected from the group consisting of A) chondroitin sulfate or a salt thereof, glycyrrhizic acid or a salt thereof, tocopherol acetate, aspartic acid or a salt thereof, epsilon aminocaproic acid or a salt thereof, and aminoethylsulfonic acid or a salt thereof. Eyewash containing at least one or more of the following. Such an eyewash is more preferably used in combination of two or more of these compounds because the effect of suppressing the adhesion of microorganisms is enhanced. Examples of the salt include alkali metals such as sodium and potassium, alkaline earth metals such as calcium and magnesium, and salts with metals such as aluminum. Sodium salts, potassium salts and magnesium salts are preferably used. These are known compounds usually used in ophthalmic compositions, and commercially available ones can also be obtained.

The chondroitin sulfate or salt thereof used in the present invention preferably has an average molecular weight in the range of 300 to 8 million, more preferably in the range of 500,000 to 5 million, and particularly preferably in the range of 1 million to 3 million. preferable. The content of chondroitin sulfate or a salt thereof in the eye wash varies depending on the molecular weight, type, etc., and thus cannot be specified unconditionally, but the concentration in the eye wash is preferably 0.001 to 5%, more preferably 0.005. It can be used at 1%, more preferably 0.005 to 0.1%, particularly preferably about 0.005 to 0.05%.
Glycyrrhizic acid or a salt thereof is preferably 0.001 to 1%, more preferably 0.001 to 0.5%, still more preferably 0.005 to 0.1%, particularly preferably as a concentration in the eye wash. It can be used at about 0.005 to 0.025%.
As the tocopherol acetate used in the present invention, any compound such as α-, β-, and γ-tocopherol can be used as d-form or l-form, and tocopherol acetate can be used alone or in appropriate combination of two or more. You can also. Tocopherol acetate is preferably 0.0001 to 0.5%, more preferably 0.0001 to 0.05%, still more preferably 0.0005 to 0.01%, particularly preferably 0 as the concentration in the eyewash. .0005 to 0.005%.
Aspartic acid or a salt thereof is preferably 0.001 to 5%, more preferably 0.005 to 1%, still more preferably 0.005 to 0.5%, and particularly preferably 0.005 as a concentration in the eye wash. It can be used at about 01 to 0.1%.
Epsilon aminocaproic acid or a salt thereof is preferably 0.001 to 10%, more preferably 0.005 to 5%, still more preferably 0.01 to 3%, particularly preferably 0.1 as the concentration in the eyewash. About 0.5% can be used.
Aminoethylsulfonic acid or a salt thereof is preferably 0.001 to 3%, more preferably 0.005 to 1%, still more preferably 0.01 to 0.5%, particularly preferably as a concentration in the eye wash. It can be used at about 0.01 to 0.1%.

  In the eyewash set of the present invention, the eyewash solution is characterized in that the viscosity is adjusted and the viscosity at 20 ° C. is 2 mPa · s or more and 15 mPa · s or less. More preferably, it is 3-15 mPa * s, More preferably, it is 3-10 mPa * s. By adjusting to such a specific viscosity range, an excellent microbial adhesion suppressing effect is exhibited.

  A known method can be used as the viscosity measuring method. For example, a method using a conical one-plate rotary viscometer (general test method, 45. Viscosity measuring method, second method described in the 14th revised Japanese pharmacy method) It can be measured according to the rotational viscometer method, the method described in the section “(3) Cone-Plate type rotational viscometer”. In measuring viscosity, commercially available viscometers such as E-type viscometers (manufactured by TOKIMEC, sold by Toki Sangyo (Japan)), Synchronic PC type (Brookfield, USA), Ferranti Shirley (Feranti, UK), Rot Bisco R (Haake, Germany), IGK Hischer Rheometer (Ishida Giken, Japan), Shimadzu Rheometer R (Shimadzu, Japan), Weissenberg Greogoniometer (Sangamo, UK), Mechanical Spectro Meters (rheometrics, rice), etc. can be used. Then, by appropriately selecting these commercially available viscometers and rotors, by appropriately adjusting the petroleum-based hydrocarbon oil (Newtonian fluid) defined by JIS Z8809 for each test sample measurement as a calibration standard solution, The viscosity at 20 ° C. can be measured.

  The eyewash solution of the present invention contains at least one selected from hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone or polyvinyl alcohol, thereby enhancing the effect of suppressing microbial adhesion. These are known compounds usually used in ophthalmic compositions, and commercially available ones can also be obtained.

  In the present invention, the content of these compounds in the eye wash varies depending on the type and molecular weight of the compound and is not limited. However, the content of each compound is preferably 0 for hydroxyethyl cellulose. 0.001 to 2%, more preferably 0.01 to 1%, particularly preferably about 0.05 to 0.5%. The content of hydroxypropylmethylcellulose is preferably about 0.001 to 2%, more preferably about 0.01 to 1%, and particularly preferably about 0.05 to 0.5%. The content of methylcellulose is preferably about 0.01 to 1%, more preferably about 0.05 to 0.5%. The content of polyvinyl pyrrolidone is preferably 0.001 to 10%, more preferably 0.01 to 5%, still more preferably about 0.05 to 3%, and the content of polyvinyl alcohol is 0.01 to 10%. More preferably, it is about 0.05 to 2%.

  In the present invention, preferably, hydroxyethyl cellulose having a viscosity of 20% at 2 ° C. and a 2% aqueous solution of 100 mPa · s to 50000 mPa · s is used, more preferably 1000 mPa · s to 50000 mPa · s, and particularly preferably 1000 mPa · s. ˜30000 mPa · s of hydroxyethyl cellulose is used. Commercially available hydroxyethyl cellulose can be used, for example, HEC-CF-G (20 ° C., 2% aqueous solution viscosity is 300 mPa · s to 600 mPa · s) sold by Sumitomo Seika Co., Ltd., HEC -CF-V (viscosity of 2% aqueous solution at 20 ° C. is 5000 mPa · s to 10,000 mPa · s), HEC-CF-W (viscosity of 2% aqueous solution at 20 ° C. is 10,000 mPa · s to 16000 mPa · s), etc. can be used. .

  In the present invention, preferably, methylcellulose having an average molecular weight of 50,000 to 500,000 is used. More preferably, methylcellulose having an average molecular weight of 100,000 to 500,000 and particularly preferably 200,000 to 500,000 is used. Commercially available methylcellulose can be used. For example, SM-15 (average molecular weight of about 70,000), SM-25 (average molecular weight of about 90,000) sold by Shin-Etsu Chemical Co., Ltd. as the Metrows SM series. ), SM-50 (average molecular weight of about 110,000), SM-100 (average molecular weight of about 120,000), SM-400 (average molecular weight of about 170,000), SM-1500 (average molecular weight of about 290,000), SM-4000 (Average molecular weight of about 360,000) can be used.

  In the present invention, it is preferable to use a known polyvinyl pyrrolidone having an average molecular weight of 10,000 to 150,000. More preferably, polyvinylpyrrolidone having an average molecular weight of 20,000 to 150,000 is used. Commercially available polyvinyl pyrrolidone can be used. For example, Kollidon 12PF (average molecular weight of about 20,000) and Kollidon 17PF (average molecular weight of about 90,000) sold by BASF Corporation as the Kollidon series. Kollidon 25 (average molecular weight of about 30,000), Kollidon 30 (average molecular weight of about 50,000), Kollidon 90 (average molecular weight of about 120,000) and the like can be used.

  In the present invention, it is preferable to use a known hydroxypropylmethylcellulose having an average molecular weight of 50,000 to 500,000. More preferred is hydroxypropylmethylcellulose having an average molecular weight of 100,000 to 500,000, particularly preferably 200,000 to 500,000. Commercially available hydroxypropylmethylcellulose can be used, for example, 60SH-15 (average molecular weight of about 70,000), 60SH-25 (average molecular weight of about 70,000 sold by Shin-Etsu Chemical Co., Ltd. as the Metrows SH series. 90,000), 60SH-50 (average molecular weight of about 110,000), 60SH-100 (average molecular weight of about 120,000), 60SH-400 (average molecular weight of about 170,000), 60SH-1500 (average molecular weight of about 290,000), 60SH- 4000 (average molecular weight of about 360,000) can be used.

  In the present invention, it is preferable to use a known polyvinyl alcohol having an average molecular weight of 10,000 to 300,000. More preferably, polyvinyl alcohol having an average molecular weight of 30,000 to 200,000 is used. Commercially available polyvinyl alcohol can be used. For example, GOHSENOL EG05 (average molecular weight of about 30,000), GOHSENOL EG40 (average molecular weight of about 120,000) sold by Nippon Synthetic Chemical Co., Ltd. as Gohsenol series. ) Etc. can be used.

  The effect of inhibiting the adhesion of microorganisms of the present invention becomes more remarkable when edetic acid or a salt thereof is contained in the eye wash. Examples of such edetic acid or a salt thereof include edetic acid (ethylenediaminetetraacetic acid, EDTA), ethylenediaminediacetic acid (EDDA), diethylenetriaminepentaacetic acid (DTPA), N- (2-hydroxyethyl) ethylenediaminetriacetic acid (HEDTA), and the like. Can be illustrated. These may be used alone or in combination, and may be used as a pharmacologically or physiologically acceptable salt (for example, sodium ethylenediaminetetraacetate). Among them, ethylenediaminetetraacetic acid or a salt thereof is preferable, for example, ethylenediaminetetraacetic acid disodium, ethylenediaminetetraacetic acid disodium dihydrate (hereinafter also referred to as sodium edetate).

  Although the content of edetic acid or a salt thereof in the eyewash of the present invention varies depending on the molecular weight and type, it cannot be specified unconditionally, but for example 0.0001 to 1%, preferably 0.001 to 0.5%, particularly preferably Is about 0.005 to 0.3%.

  The effect of suppressing the adhesion of microorganisms of the present invention becomes more prominent when a nonionic surfactant is contained in the eyewash. As such a nonionic surfactant, those which can be used for eye drops by those skilled in the art can be used. For example, polyoxyethylene (hereinafter also referred to as POE) -polyoxypropylene (hereinafter also referred to as POP). ) Block copolymer (eg, poloxamer 407, poloxamer 235, poloxamer 188, etc.); POE-POP block copolymer adduct of ethylenediamine such as poloxamine; POE (20) sorbitan monolaurate (polysorbate 20), POE monooleate (20) POE sorbitan fatty acid esters such as sorbitan (polysorbate 80), POE sorbitan monostearate (polysorbate 60), POE sorbitan tristearate (polysorbate 65); POE cured castor oil 5, POE cured castor oil 10, POE cured castor oil 20 , PO POE hydrogenated castor oil such as hydrogenated castor oil 40, POE hydrogenated castor oil 50, POE hydrogenated castor oil 60, POE hydrogenated castor oil 100; POE alkyl ethers such as POE (9) lauryl ether; POE (20) POP (4 ) POE / POP alkyl ethers such as cetyl ether; POE alkylphenyl ethers such as POE (10) nonylphenyl ether. The numbers in parentheses indicate the number of added moles.

  Among them, nonionic surfactants selected from polyoxyethylene-polyoxypropylene block copolymers, POE sorbitan fatty acid esters or POE hydrogenated castor oils are preferable, and polyoxyethylene-polyoxypropylene blocks are particularly preferable. Copolymer, polysorbate 80, polyoxyethylene hydrogenated castor oil 60.

  In the eyewash of the present invention, the content of the nonionic surfactant varies depending on the type of the surfactant and the like, and thus cannot be defined unconditionally, but is usually 0.001 to 5%, preferably 0.001 to 1%. Preferably it is used at about 0.005 to 0.5%.

    When the eyewash of the present invention contains at least one selected from menthol, camphor, geraniol or borneol, the effect of inhibiting microbial adhesion is further enhanced. These compounds may be either d-form or l-form. In the eye wash of the present invention, the content of each compound is preferably 0.001 to 1%, more preferably 0.001 to 0.5%, and particularly preferably 0.001 to 0.00. About 1%. The content of camphor is preferably about 0.001 to 1%, more preferably about 0.001 to 0.5%, and particularly preferably about 0.001 to 0.1%. The content of geraniol is preferably 0.0005 to 0.1%, more preferably 0.001 to 0.05%, and particularly preferably about 0.001 to 0.01%. The content of borneol is preferably 0.001 to 1%, more preferably 0.001 to 0.5%, and particularly preferably about 0.005 to 0.5%.

The eye wash of the present invention is suitable for containing various components (including pharmacologically active components and physiologically active components) in combination. Decongestant component, ophthalmic modifier component, anti-inflammatory component or astringent component, antihistamine component or antiallergic component, vitamins, amino acids, antibacterial component, bactericidal component, saccharide, etc. Can be illustrated. Specifically, the following components can be exemplified.

Decongestant: For example, α-adrenergic agonists, specifically epinephrine, epinephrine hydrochloride, ephedrine hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, naphazoline hydrochloride, phenylephrine hydrochloride, methylephedrine hydrochloride, epinephrine hydrogen tartrate, naphazoline nitrate. These may be d-form, l-form or dl-form.
Eye muscle modulator component: For example, cholinesterase inhibitor having an active center similar to acetylcholine, specifically, neostigmine methyl sulfate, tropicamide, atropine sulfate helenien, and the like.
Anti-inflammatory component or astringent component: for example, zinc sulfate, zinc lactate, allantoin, indomethacin, lysozyme chloride, silver nitrate, pranoprofen, sodium azulenesulfonate, diclofenac sodium, bromfenac sodium, berberine chloride, berberine sulfate and the like.
Antihistamine component or antiallergic agent component: for example, acitazanolast, amlexanox, ibudilast, tranilast, diphenhydramine hydrochloride, levocabastine hydrochloride, ketotifen fumarate, sodium cromoglycate, pemirolast potassium, chlorpheniramine maleate and the like.
Vitamins: for example, retinol palmitate, pyridoxine hydrochloride, sodium flavin adenine dinucleotide, pyridoxal phosphate, cyanocobalamin, panthenol, calcium pantothenate, sodium pantothenate, ascorbic acid and the like.
Amino acids: For example, glutamic acid, creatinine, sodium glutamate and the like. These may be d-form, l-form or dl-form.
Antibacterial or bactericidal component: for example, alkylpolyaminoethylglycine, berberine sulfate, berberine chloride, boric acid, sulfamethoxazole, sulfamethoxazole sodium, sulfisoxazole, sulfisomidine sodium, etc. .
Sugars: for example, monosaccharides, disaccharides, specifically glucose, trehalose and the like.
Local anesthetic components: for example, oxybuprocaine hydrochloride, cocaine hydrochloride, cornecaine hydrochloride, dibucaine hydrochloride, tetracaine hydrochloride, diethylaminoethyl parabutylaminobenzoate, piperocaine hydrochloride, procaine hydrochloride, proparacaine hydrochloride, hexothiocaine hydrochloride, lidocaine hydrochloride.

  In addition, the eyewash of the present invention contains various components and additives as appropriate according to conventional methods and forms within a range that does not impair the effects of the invention, and contains one or more in combination. You may let them. As these components or additives, for example, various additives such as thickeners, sugars, surfactants, preservatives, bactericides or antibacterial agents, pH regulators, tonicity agents, perfumes or refreshing agents, buffering agents, etc. An agent can be mentioned.

Although the typical component used for the eyewash of this invention below is illustrated, it is not limited to these.
Thickener: for example, alginic acid or a salt thereof, propylene glycol alginate, ethyl cellulose, sodium carboxymethyl cellulose, xanthan gum, cyclodextrin, glycerin, hydroxypropyl cellulose, polyethylene glycol, carboxyvinyl polymer, alginic acid and the like.
Sugars: for example, glucose, cyclodextrin and the like.
Sugar alcohols: For example, xylitol, sorbitol, mannitol and the like.
Surfactant: For example, glycine-type amphoteric surfactant such as alkyldiaminoethylglycine; alkyl quaternary ammonium salt (specifically, cationic surfactant such as benzalkonium chloride, benzethonium chloride, etc.) The number indicates the number of moles added.
Preservatives, bactericides or antibacterials: for example, alkyldiaminoethylglycine hydrochloride, sodium benzoate, ethanol, benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorobutanol, sorbic acid, potassium sorbate, sodium dehydroacetate, paraoxy Methyl benzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, oxyquinoline sulfate, phenethyl alcohol, benzyl alcohol, biguanide compounds (specifically, polyhexamethylene biguanide, etc.), Glowyl (product of Rhodia) Name) etc.
pH adjuster: For example, hydrochloric acid, boric acid, aminoethylsulfonic acid, epsilon-aminocaproic acid, acetic acid, sodium hydroxide, sodium hydrogen carbonate, sodium carbonate, borax, triethanolamine, monoethanolamine and the like.
Isotonizing agents: for example, sodium bisulfite, sodium sulfite, potassium chloride, calcium chloride, sodium chloride, magnesium chloride, potassium acetate, sodium acetate, sodium bicarbonate, sodium carbonate, sodium thiosulfate, magnesium sulfate, dihydrogen phosphate Sodium, sodium dihydrogen phosphate, potassium dihydrogen phosphate, glycerin, propylene glycol and the like.
Perfume or refreshing agent: for example, menthol, camphor, borneol, geraniol, agate, fennel oil, cool mint oil, spearmint oil, peppermint water, peppermint oil, peppermint oil, bergamot oil, eucalyptus oil, rose oil and the like. These may be d-form, l-form or dl-form.
Buffer: aminoethyl sulfonic acid, epsilon-aminocaproic acid, citrate buffer, acetate buffer, carbonate buffer, borate buffer, phosphate buffer, etc. Specifically, citric acid, sodium citrate, acetic acid, potassium acetate, sodium acetate, sodium hydrogen carbonate, sodium carbonate, boric acid, borax, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate Such.
Stabilizer: Dibutylhydroxytoluene, trometamol, sodium formaldehyde sulfoxylate (Longalite), tocopherol, sodium pyrosulfite, monoethanolamine, aluminum monostearate, etc.
Solubilizer, base: octyldodecanol, titanium oxide, potassium bromide, paraffin, castor oil, plastibase, lanolin, petrolatum, etc.

  The eye wash of the present invention is used by adjusting to an osmotic pressure within a range acceptable for a living body, if necessary. The osmotic pressure is about 100 to 1200 mOsm, preferably about 100 to 600 mOsm, particularly preferably about 150 to 400 mOsm, and the osmotic pressure ratio with respect to physiological saline is usually 0.3 to 4.1, preferably 0.3 to 2. 1, particularly preferably about 0.5 to 1.4.

  The eye wash of the present invention is used after adjusting the pH as necessary. The pH is 4.0 to 10.0, preferably 5.0.0 to 9.0, particularly preferably 6.0 to 8.0. The pH can be adjusted using a buffer, the pH adjuster, or the like.

  Here, examples of the buffer include borate buffer, phosphate buffer, carbonate buffer, citrate buffer, and acetate buffer. Preferred buffering agents are borate buffer, phosphate buffer, carbonate buffer and citrate buffer. Particularly preferred buffering agents are borate buffers or phosphate buffers. Examples of the boric acid buffer include borates such as boric acid, alkali metal borates, and alkaline earth metal borates, and combinations of boric acid and borates. Examples of the phosphate buffer include phosphates such as phosphoric acid, alkali metal phosphates, and alkaline earth metal phosphates, and combinations of phosphoric acid and phosphates. Moreover, you may use the borate or the hydrate of a phosphate as a borate buffer or a phosphate buffer. More specifically, boric acid or a salt thereof (sodium borate, potassium tetraborate, potassium metaborate, etc.), phosphoric acid or a salt thereof (sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, etc.) , Carbonic acid or a salt thereof (sodium bicarbonate, sodium carbonate, etc.), citric acid or a salt thereof (sodium citrate, potassium citrate, etc.).

  The eye wash of the present invention can be produced by a known method. Furthermore, if necessary, a filtration sterilization treatment process, a container filling process, and the like can be added. Furthermore, an eyewash set can be manufactured by combining with an eyewash cup.

  Hereinafter, the present invention will be described in detail based on test examples and examples, but the present invention is not limited to these examples.

Viscosity measurement method Viscosity measurement method is a method using a cone-and-plate rotational viscometer (general test method, 45. Viscosity measurement method, second method rotational viscometer method described in the 14th revised Japanese pharmacy method, "( 3) The method described in the section “Cone-plate rotational viscometer” was followed. The viscosity of each comparative example and each example in this test is a TVE-20L type viscometer cone plate type (manufactured by TOKIMEC, Toki Sangyo (Japan)), which is a type of E-type viscometer. Measurement was performed under the following measurement conditions.

Measurement condition:
Standard cone rotor (corresponding to cone 1 in Fig. 1) (α = 1 ° 34 ', radius (R) = 2.4cm) attached to TVE-20L type viscometer cone plate type, full scale torque 67.37 × 10 ^-6 Rotate by motor through Nm spring. During measurement, the viscometer is installed so that the rotation axis is perpendicular to the horizontal plane.
1 ml of the test sample is placed on a predetermined position of the cone rotor (a plate, which corresponds to the flat disk 2 in FIG. 1) and left until the temperature reaches 25.0 ° C. Next, the apparatus is rotated at a rotation speed corresponding to the viscosity of the test sample, and after 4 minutes, the displayed viscosity is read. In order to obtain highly accurate measurement results, use a petroleum-based hydrocarbon oil (Newtonian fluid) stipulated by JIS Z 8809 as the standard solution for calibration before measuring the test sample, and the measured value is the viscosity of the standard solution. Adjust to match. The same result can be obtained by using a commercially available model other than the TVE-20L viscometer cone plate type, selecting a cone rotor in the same manner as described above, and performing calibration appropriately.
Rotor used: Standard rotor (1 ° 34 ', R = 24mm)
Rotation speed: 50rpm
Sample volume: 1 ml
Measurement temperature: 20 ° C
Time: Viscosity after 3 minutes was taken as a measured value.

Test Example 1 Microorganism Adhesion Inhibitory Effect Test The test bacterium used was Pseudomonas aerginosa ATCC9027. The test solution was prepared based on the formulation shown in Table 1 (pH = 7.5).
The test method was as follows (the test was performed with n = 5).
(1) Each test solution was filled in a low-substituted polyethylene eyewash cup sterilized with alcohol and immersed for 4 hours.
(2) The test solution in the eyewash cup was discarded, and 5 mL of the test bacterial solution adjusted to 1 × 10 ⁷ CFU / mL was added to the test solution and allowed to stand for 30 minutes.
(3) After standing, it was washed 3 times with 5 mL of sterilized purified water, and then 5 mL of new sterilized physiological saline was added, treated with ultrasound for 3 minutes, and then vigorously stirred with vortex for 1 minute.
(4) The viable cell count of the physiological saline solution of (3) above was appropriately diluted and measured by the membrane filter method to obtain the adhering cell count. The adhesion inhibition rate (%) was the ratio obtained by dividing the number of adherent bacteria in the test solution (comparative example or example) by the number of adherent bacteria in the control test solution. The results are shown in Table 1.

  As a result of the test, the present invention contains a combination of potassium L-aspartate, aminoethylsulfonic acid, sodium chondroitin sulfate, acetic acid-d-α-tocopherol or dipotassium glycyrrhizinate, and a viscosity at 20 ° C. of 2 to 12 mPa · s. In this example, it was confirmed that the adhesion of Pseudomonas aeruginosa to the eyewash cup was significantly suppressed.

Example 6
Dipotassium glycyrrhizinate 0.02%, potassium L-aspartate 0.1%, chlorpheniramine maleate 0.003%, aminoethylsulfonic acid 0.04%, boric acid 1.5%, borax 0.3%, l-menthol 0.02%, d-camphor 0.001 %, Polysorbate 80 0.1%, sodium edetate 0.005%, hydroxypropylmethylcellulose 2906 0.4%, benzalkonium chloride 0.01%, chlorobutanol 0.005%, hydrochloric acid / sodium hydroxide appropriate amount, purified water appropriate amount (viscosity 10mPa -An eye wash set was made by combining s) and a polyvinyl acetate eye wash cup. In such an eyewash set, adhesion of microorganisms to the eyewash cup was suppressed.

Example 7
Glycyrrhizinate dipotassium 0.02%, L-aspartate potassium 0.1%, acetic acid d-α-tocopherol 0.005%, pyridoxine hydrochloride 0.01%, aminoethylsulfonic acid 0.06%, chondroitin sodium sulfate 0.02%, boric acid 1.5%, borax 0.3 %, L-menthol 0.01%, dl-camphor 0.05%, polysorbate 80 0.3%, sodium edetate 0.005%, hydroxypropylmethylcellulose 2906 0.4%, benzalkonium chloride 0.01%, hydrochloric acid / sodium hydroxide appropriate amount, purified water appropriate amount The prepared eyewash (viscosity 10 mPa · s) and a silicone rubber eyewash cup were combined to make an eyewash set. In such an eyewash set, adhesion of microorganisms to the eyewash cup was suppressed.

Example 8
Glycyrrhizinate dipotassium 0.025%, L-aspartate potassium 0.08%, dd-α-tocopherol acetate 0.005%, pyridoxine hydrochloride 0.005%, aminoethylsulfonic acid 0.02%, chondroitin sulfate 0.05%, boric acid 1.5%, borax 0.3 %, L-menthol 0.008%, dl-camphor 0.01%, polysorbate 80 0.3%, sodium edetate 0.01%, hydroxypropylmethylcellulose 2906 0.2%, benzalkonium chloride 0.01%, hydrochloric acid / sodium hydroxide appropriate amount, purified water appropriate amount The prepared eyewash (viscosity 4 mPa · s) and an eyewash cup made of styrene thermoplastic elastomer resin were combined to make an eyewash set. In such an eyewash set, adhesion of microorganisms to the eyewash cup was suppressed.

Example 9
Dipotassium glycyrrhizate 0.01%, epsilon aminocaproic acid 0.25%, potassium L-aspartate 0.05%, chlorpheniramine maleate 0.003%, aminoethylsulfonic acid 0.1%, boric acid 1.5%, borax 0.3%, l-menthol 0.01 %, D-borneol 0.001%, polysorbate 80 0.2%, sodium edetate 0.01%, hydroxypropylmethylcellulose 2906 0.3%, benzalkonium chloride 0.01%, chlorobutanol 0.01%, hydrochloric acid / sodium hydroxide appropriate amount, purified water appropriate amount The eyewash solution (viscosity 6 mPa · s) and a low-substituted polyethylene eyewash cup were combined to make an eyewash set. In such an eyewash set, adhesion of microorganisms to the eyewash cup was suppressed.

Claims (6)

Containing at least one selected from the group consisting of chondroitin sulfate or a salt thereof, glycyrrhizic acid or a salt thereof, tocopherol acetate, aspartic acid or a salt thereof, epsilon aminocaproic acid or a salt thereof, and aminoethylsulfonic acid or a salt thereof; An eye wash set in which an eye wash having a viscosity at 20 ° C. of 2 mPa · s to 15 mPa · s and an eye wash cup are combined. The eye wash set according to claim 1, wherein the eye wash has a viscosity at 20 ° C of from 3 mPa · s to 10 mPa · s. The eye wash set according to claim 1 or 2, wherein the eye wash contains at least one selected from the group consisting of hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, and polyvinyl alcohol. 4. The eye wash further contains a nonionic surfactant selected from polyoxyethylene-polyoxypropylene block copolymers, polyoxyethylene sorbitan fatty acid esters or polyoxyethylene hydrogenated castor oils. Eye wash set. The eye wash set according to any one of claims 1 to 4, wherein the eye wash further contains edetic acid or a salt thereof. The eye wash set according to any one of claims 1 to 5, wherein the eye wash further contains at least one selected from menthol, camphor, geraniol, or borneol.